Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News GH Research PLC GHRS

Healthcare
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GHRS)

GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire 12 hours ago

GH Research Reports Second Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire September 3, 2024

GH Research Announces Appointment of Dr. Velichka "Villy" Valcheva to Chief Executive Officer

GlobeNewswire September 3, 2024

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

GlobeNewswire May 3, 2024

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire February 29, 2024

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

GlobeNewswire January 18, 2024

GH Research Reports Third Quarter Financial Results and Provides Business Updates

GlobeNewswire November 9, 2023

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

GlobeNewswire September 29, 2023

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

GlobeNewswire August 23, 2023
View More News ››

Opinion & Analysis (NDAQ:GHRS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GHRS)

GH Research Reports First Quarter 2024 Financial Results and

News; $GHRS GH Research Reports First Quarter 2024 Financial Results and Provides Business UpdatesPhase 2b clinical trial of GH001 in...
whytestocks - May 3, 2024
View more Bullboard ››

EnviroGold Global Limited.

EnviroGold Global Limited.

EnviroGold Global Limited is a Canadian headquartered clean technology company with a global vision and a strategic focus ...
View More »